1.	Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000491233, RTOG-0517, NCT00365105
2.	Phase I/II Study of Samarium 153 and Autologous Bone Marrow Transplantation in Women With Stage IV Breast Cancer (Summary Last Modified 04/2002). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 21-65 Sponsor: Other Protocol IDs: LSU-97447, NCI-V97-1341, NCT00003086
3.	Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000546736, P30CA015083, MC0585, 1586-05, MAYO-MC0585, MAYO-IRB-1586-05, NCT00478075
4.	Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000546769, P30CA015083, MC048B, 261-05, MAYO-MC048B, MAYO-IRB-261-05, NCT00482378
5.	Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000582552, P30CA015083, MC9981, 1046-99, MAYO-MC9981, NCT00602706
6.	Phase II Study of Samarium Sm 153 Lexidronam Pentasodium (153Sm-lexidronam) in Combination with Total Androgen Blockade in Patients with Stage D2 Prostate Carcinoma (Summary Last Modified 06/98) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CYTOGEN-424Sm17, NCI-V97-1255
7.	Samarium Sm 153 Lexidronam Pentasodium and Autologous Stem Cell Transplant Followed By Radiation Therapy in Treating Patients With Recurrent or Refractory, Metastatic, or Unresectable Osteosarcoma Phase: Phase II Type: Treatment Status: Completed Age: 13 to 50 Sponsor: NCI, Other Protocol IDs: J0347 CDR0000447134, JHOC-J0347, JHOC-03090802, J0347, NCT00245011
8.	153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: 070106, 07-C-0106, NCI-07-C-0106, 7678, NCT00450619
9.	Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases Phase: Phase II Type: Behavioral study, Treatment Status: Closed Age: 18 to 65 Sponsor: Other Protocol IDs: 2006-0349, NCT00429507
10.	Phase I Study of 153Sm-EDTMP in Children with Refractory Malignancies and Painful Osseous Lesions (Summary Last Modified 07/97) Phase: Phase I Type: Supportive care, Treatment Status: Completed Age: over 5 to 25 Sponsor: NCI Protocol IDs: NCI-95-C-0113A
11.	Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000479712, ONCOTHER-20051780, ONCOTHER-424Sm35, CYTOGEN-ONCOTHER-20051780, NCT00316940
12.	Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 02C.172, 2001-114, NCT00328614
13.	Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 to 80 Sponsor: Other Protocol IDs: J0467, 04-09-03-03, NCT00559429